Zobrazeno 1 - 10
of 28
pro vyhledávání: '"Seung Yon Han"'
Autor:
Choong Whan Lee, Byoung Hoon You, Sreymom Yim, Seung Yon Han, Hee-Sung Chae, Mingoo Bae, Seo-Yeon Kim, Jeong-Eun Yu, Jieun Jung, Piseth Nhoek, Hojun Kim, Han Seok Choi, Young-Won Chin, Hyun Woo Kim, Young Hee Choi
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Metformin as an oral glucose-lowering drug is used to treat type 2 diabetic mellitus. Considering the relatively high incidence of cardiovascular complications and other metabolic diseases in diabetic mellitus patients, a combination of metformin plu
Externí odkaz:
https://doaj.org/article/be0f3aa1c24744ada15f7c1d1b096b69
Autor:
Seung Yon Han, Jeong-Eun Yu, Byoung Hoon You, Seo-Yeon Kim, Mingoo Bae, Hee-Sung Chae, Young-Won Chin, Soo-Hwa Hong, Ju-Hee Lee, Seung Hyun Jung, Young Hee Choi
Publikováno v:
International Journal of Molecular Sciences, Vol 24, Iss 23, p 16677 (2023)
Trastuzumab is used to treat breast cancer patients overexpressing human epidermal growth factor receptor 2, but resistance and toxicity limit its uses, leading to attention to trastuzumab combinations. Recently, the synergistic effect of trastuzumab
Externí odkaz:
https://doaj.org/article/386c84a0f6b24443a3917b4ecd70ef83
Publikováno v:
Pharmaceutics, Vol 15, Iss 9, p 2277 (2023)
Mirabegron (MBR) is a β3-adrenoceptor agonist used for treating overactive bladder syndrome. Due to its poor solubility and low bioavailability (F), the development of novel MBR formulations has garnered increasing attention. Recently, co-amorphous
Externí odkaz:
https://doaj.org/article/b2fcb3f8333340c39f0a54390dbeeebd
Publikováno v:
Pharmaceutics, Vol 15, Iss 8, p 2167 (2023)
Febuxostat (FBX), a selective xanthine oxidase inhibitor, belongs to BCS class II, showing low solubility and high permeability with a moderate F value (F) values of FBX were 210% and 159% in FBX-PG-treated rats and mice, respectively. The 2.10-fold
Externí odkaz:
https://doaj.org/article/dc425f5debcc449b8107e262e0c3f9ea
Publikováno v:
Pharmaceutics, Vol 15, Iss 5, p 1392 (2023)
Tenofovir (TEV) is a nucleotide reverse transcriptase inhibitor used against human immunodeficiency virus (HIV) reverse transcriptase. To improve the poor bioavailability of TEV, TEV disoproxil (TD), an ester prodrug of TEV, was developed, and TD fum
Externí odkaz:
https://doaj.org/article/02bd8c0ac9d445618521f861c01f58ac
Autor:
Mingoo Bae, Seung Yon Han, Eun-Sun Kim, Byung Hoon You, Young-Mi Kim, Jungsook Cho, Young-Won Chin, Young Hee Choi
Publikováno v:
Molecules, Vol 26, Iss 17, p 5246 (2021)
The pharmacokinetic (PK) change in a drug by co-administered herbal products can alter the efficacy and toxicity. In the circumstances that herb–drug combinations have been increasingly attempted to alleviate Alzheimer’s disease (AD), the PK eval
Externí odkaz:
https://doaj.org/article/f639b72d65054165bc0fe40086c21375
Autor:
Seung Yon Han, Young Hee Choi
Publikováno v:
Pharmaceutics, Vol 12, Iss 5, p 468 (2020)
The incidence of hypertension in diabetic patients has been increasing and contributing to the high mortality of diabetic patients. Recently, verapamil use was found to lower fasting blood glucose levels in diabetic patients, which led to a new indic
Externí odkaz:
https://doaj.org/article/9ab3fb1791e34bbcb12566005123bf99
Publikováno v:
Pharmaceutics, Vol 11, Iss 3, p 135 (2019)
P-glycoprotein (P-gp)-mediated efflux of docetaxel in the gastrointestinal tract mainly impedes its oral chemotherapy. Recently, LC478, a novel di-substituted adamantyl derivative, was identified as a non-cytotoxic P-gp inhibitor in vitro. Here, we a
Externí odkaz:
https://doaj.org/article/13f3ce5ec9ce4aa4b61edeaa0bc84ae9
Publikováno v:
PLoS ONE, Vol 10, Iss 7, p e0131587 (2015)
The information about a marker compound's pharmacokinetics in herbal products including the characteristics of absorption, distribution, metabolism, excretion (ADME) is closely related to the efficacy/toxicity. Also dose range and administration rout
Externí odkaz:
https://doaj.org/article/e95ba7c46466439685148e5a1084031a
Autor:
Young Hee Choi, Qili Lu, Hee-Sung Chae, Eun-Sun Kim, Byoung Hoon You, Kyeong Lee, Young-Won Chin, Suk-Jae Chung, Hee-Chul Ahn, Seung Yon Han
Publikováno v:
Xenobiotica. 50:863-874
1. Treatment periods of P-glycoprotein (P-gp) inhibitors have revealed different efficacies. We have previously reported dose-dependent inhibition of P-gp in single-treatment with LC478. However, whether repeated treatment with LC478 can inhibit P-gp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92f58c034dacbbe0c5fddd7a7fb293bc
https://doi.org/10.1080/00498254.2019.1700318
https://doi.org/10.1080/00498254.2019.1700318